ESPE Abstracts

ESPE Abstracts

Published by BioScientifica
Previous issue | Volume 92 | ESPE2019 | Next issue

58th Annual ESPE (ESPE 2019)

Vienna, Austria
19 Sept 2019 - 21 Sept 2019

Card image cap
The theme of this year’s meeting is Variety and Variation in Paediatric Endocrinology. Join us in Vienna to explore the diversity we encounter in our discipline and the care that we have to exercise when using the term “normality”. Whilst gaining an update on the latest treatments, clinical best practice and cutting edge research in the field of paediatric endocrinology.

Poster Category 1

GH and IGFs (2)

Previous section
Fat, Metabolism and Obesity (2)
Table of contents
Next section
Growth and Syndromes (to include Turner Syndrome) (2)

hrp0092p1-359 | GH and IGFs (2)

Insulin-Like Growth Factor 2 in Pediatric Gliomas: Expression, Intracellular Localization and Association with Clinical Outcome

hrp0092p1-360 | GH and IGFs (2)

Prevalence of Children Born Small for Gestational Age with Short Stature who Qualify for Growth Hormone Treatment: A Preliminary Population-Based Study

hrp0092p1-361 | GH and IGFs (2)

Long-Term Safety of a Once-Weekly Somatrogon (hGH-CTP): 4-Year Results of a Phase 2 Extension Study in Children with Growth Hormone Deficiency

hrp0092p1-362 | GH and IGFs (2)

Sequencing Approach to Identify Candidate Genes Involved in Short Stature

hrp0092p1-363 | GH and IGFs (2)

Metabolism of Somapacitan, a Long-Acting Growth Hormone Derivative, in Human Subjects

hrp0092p1-364 | GH and IGFs (2)

GH Values in Serum and Blood Spots on Filter Paper Samples in Neonates Until 30 Days of Life by Electrochemiluminescence (ECLIA).

hrp0092p1-365 | GH and IGFs (2)

De Novo Formation of Neutralizing IGF-I Antibodies During rhIGF-1 Treatment in a Girl with IGFALS Deficiency as Distinct Adverse Event Interfering with Growth Promotion

hrp0092p1-366 | GH and IGFs (2)

Glomerular Filtration Rate in Young Adults Born SGA: A 5-Year Longitudinal Study after Cessation of GH Treatment.

hrp0092p1-367 | GH and IGFs (2)

Normal IGF-Bioactivity and Low Free IGF-I in Patients with Prader-Willi Syndrome with High Total Serum IGF-I: Immunoreactive IGF-I Concentration Poorly Reflects IGF Bio-Activity and Bio-Availability.

hrp0092p1-368 | GH and IGFs (2)

Renal Complication of Hematuria and Proteinuria after Recombinant Human Growth Hormone Therapy in Children

hrp0092p1-369 | GH and IGFs (2)

Detection and Referral of Children with Short Stature in Serbia - the Impact of Electronic Growth Charts

hrp0092p1-370 | GH and IGFs (2)

Challenges Experienced in Delivering Growth Hormone Therapy in Children's with Prader Willi Syndrome in Birmingham Children's Hospital.

Published by BioScientifica

ESPE Abstracts

© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more